Teva to Participate in Investor Conferences in March

Teva Pharmaceutical Industries Ltd. recently made an announcement regarding the participation of Richard Francis, Teva’s President and CEO, in several investor conferences scheduled for March. The company disclosed that Richard Francis would be partaking in the UBS European Healthcare Conference, the Leerink Partners Global Healthcare Conference, and the Barclays 28th Annual Global Healthcare Conference on March 3rd, March 9th, and March 10th respectively. While the UBS conference will only have investor meetings with no webcast, both the Leerink Partners and Barclays conferences will feature webcast fireside chats.

Those interested in accessing live webcasts of these presentations can do so by visiting Teva’s Investor Relations website at https://ir.tevapharm.com/Events-and-Presentations. Additionally, archived versions of these webcasts will be made available within 24 hours post the live discussion and will remain accessible for up to 30 days.

Teva Pharmaceutical Industries Ltd., listed on the NYSE and TASE under the symbol TEVA, is currently in the midst of transforming into a pioneering innovative biopharmaceutical entity through its exceptional generics business. With a history spanning over 120 years, Teva’s unwavering commitment to improving health remains a cornerstone of its operations. Teva’s spectrum of offerings spans the fields of neuroscience and immunology, extending to the provision of intricate generic medicines, biosimilars, and pharmacy brands worldwide. The company’s dedicated efforts are centered around meeting the comprehensive needs of patients both at present and in the times ahead. At Teva, the ethos is all about striving for better health.

As is customary with such communications, a cautionary note has been issued regarding forward-looking statements contained within this document and the presentations at the upcoming conferences. These forward-looking statements, as defined by the Private Securities Litigation Reform Act of 1995, touch upon various aspects including financial guidance and management’s expectations. These statements are subject to a myriad of risks and uncertainties, known and unknown, which could potentially lead to significant deviations in Teva’s future results, performance, or accomplishments. Key factors influencing such deviations encompass the company’s competitiveness in the market, reliance on generic products, success in developing and commercializing pharmaceutical products, and the effectiveness of its patents and measures to safeguard intellectual property rights.

In conclusion, Teva Pharmaceutical Industries Ltd.’s evolution toward becoming a frontrunner in the biopharmaceutical realm underscores its unwavering dedication to enhancing the landscape of health services. With an indomitable commitment to innovation and patient-centric care, Teva is poised to continue making meaningful strides in the healthcare industry.